Advent Therapeutics Receives FDA Rare Pediatric Disease Designation for Retinol Palmitate for Prevention of Bronchopulmonary Dysplasia in Premature Infants Reinventing Vitamin A for neonatal and pediatric unmet medical needsBronchopulmonary Dysplasia (BPD) is most frequent serious complication of preterm birth – US preterm births highest in 15...

Advent Therapeutics Awarded $3 Million NIH Grant for Novel Neonatal Lung Therapy DOYLESTOWN, Pa., July 18, 2023 (GLOBE NEWSWIRE) -- Advent Therapeutics, Inc., a biotechnology company pioneering an optimized retinol palmitate (vitamin A) drug product as a breakthrough...